Home > Healthcare > Medical Devices > Operating Room Supplies > Fluorescence Guided Surgery Systems Market

Fluorescence Guided Surgery Systems Market Size

  • Report ID: GMI9171
  • Published Date: Apr 2024
  • Report Format: PDF
 Download Free Sample

Fluorescence Guided Surgery Systems Market Size

Fluorescence Guided Surgery Systems Market size was valued at USD 92.7 million in 2023 and is expected to reach USD 358.8 million by 2032 growing at a CAGR of 16.3% over the analysis period. Increasing prevalence of chronic diseases, growth in targeted surgeries for cancer and cardiovascular disorders, growing focus towards improving surgical outcomes and reducing operating time are driving the revenue growth in the market.

 

Fluorescence Guided Surgery Systems Market
To get key market trends
  Download Free Sample

Furthermore, government support and initiatives for improving healthcare infrastructure in surgical settings is also supporting the revenue growth in the market. With the global incidence of cancer on the rise, the demand for more accurate and effective surgical procedures has increased. According to the American Cancer Society, the number of cancer cases is predicted to increase from 20 million in 2022 to 35 million in 2050. Fluorescence-guided surgery systems are emerging as a promising solution, allowing surgeons to better visualize tumor margins and detect even the smallest clusters of cancer cells. As a result, the adoption of fluorescence-guided surgery systems is increasing across surgical settings.
 

Fluorescence Guided Surgery Systems Market Report Attributes
Report Attribute Details
Base Year:2023
Fluorescence Guided Surgery Systems Market Size in 2023:USD 92.7 Million
Forecast Period:2024 – 2032
Forecast Period 2024 – 2032 CAGR:16.3%
2024 – 2032 Value Projection:USD 358.8 Million
Historical Data for:2021 – 2023
No. of Pages:108
Tables, Charts & Figures:199
Segments covered:Type, Surgery, Application, and Region
Growth Drivers:
  • Increasing prevalence of chronic diseases
  • Growth in targeted surgeries for cancer and cardiovascular disorders
  • Growing focus towards improving surgical outcomes and reducing operating time
  • Government initiatives aimed at improving surgical infrastructure
Pitfalls & Challenges:
  • High cost of surgical equipment and consumables
Learn more about the key segments shaping this market
 Download Free Sample
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Fluorescence guided surgery systems industry size recorded USD 92.7 million in 2023 and is expected to depict 16.3% CAGR from 2024 to 2032, led by the increasing prevalence of chronic diseases and the growth in targeted surgeries for cancer and cardiovascular disorders

The SPY system segment in the market accumulated 55.2% share in 2023 and is estimated to grow at substantial CAGR between 2024 and 2032, due to their versatility and adaptability for catering to a range of surgical procedures and clinical environments.

North America fluorescence guided surgery systems industry is projected to be worth USD 138.6 million by 2032, owing to the presence of significant number of established vendors and advanced healthcare infrastructure.

Stryker Corporation, Olympus Corporation, KARL STORZ SE & Co. KG, Medtronic plc, Carl Zeiss Meditec AG, Danaher Corporation (Leica Microsystems), Hamamatsu Photonics K.K., Shimadzu Corporation, LI-COR, Inc., PerkinElmer Inc., Getinge (Fluoptics), OnLume Inc., Irillic Pvt. Ltd., and Curadel, LLC are some of the leading fluorescence guided surgery systems companies worldwide.

Market size for real world evidence solutions had surpassed USD 1.9 billion during 2023 and could witness 15.7% CAGR between 2024 and 2032 owing to the expanding adoption of RWE in clinical research, increasing demand for evidence-based decision-making in healthcare, coupled with the need for cost-effective and efficient drug development processes.

The drug development and approval segment will record USD 2.1 billion by 2032, primarily due to the crucial role RWE plays in enhancing the efficiency and effectiveness of clinical trials, providing valuable insights into drug performance in real-world settings.

North America real world evidence solutions industry will secure USD 2.6 billion by 2032, driven by the rising utilization of real-world evidence (RWE) solutions in clinical research, the presence of digital healthcare infrastructure facilitating the generation of ample real-time data, alongside increasing support from government and regulatory agencies like the US FDA for standardizing RWE solutions.

Some of the leading real world evidence solutions industry players include Aetion, Inc., Cognizant Technology Solutions Corporation, Elevance Health, Inc., ICON plc., IQVIA Holdings Inc., Optum, Inc., Oracle Corporation, Parexel International Corporation, PerkinElmer Inc., SAS Institute Inc., among others.

Fluorescence Guided Surgery Systems Market Scope

  • Fluorescence Guided Surgery Systems Market Size
  • Fluorescence Guided Surgery Systems Market Trends
  • Fluorescence Guided Surgery Systems Market Analysis
  • Fluorescence Guided Surgery Systems Market Share

    • Buy Now

    Premium Report Details

    • Base Year: 2023
    • Companies covered: 14
    • Tables & Figures: 199
    • Countries covered: 22
    • Pages: 108
     Download Free Sample
    ×
    Get a free sample of Fluorescence Guided Surgery Systems Market
    Inquiry Before Buying
    Get special pricing options on this report
    Request Sectional Data
    Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours below

    Your personal details will remain secure and confidential.